CIBRA Capital Ltd has significantly increased its stake in Amicus Therapeutics (NASDAQ:FOLD), acquiring an additional 1,476,861 shares valued at approximately $21.17 million, according to an SEC filing dated April 24, 2026. This move raises CIBRA’s total holdings in Amicus to 1,687,661 shares, now representing 11.78% of its assets under management (AUM) and making it the fund’s largest position.
This transaction is noteworthy as it reflects a 10.2% increase in CIBRA’s reportable AUM, driven by both the new shares purchased and a rise in Amicus’s share price. The stock has shown robust performance, boasting a 103.7% total return over the past year, significantly outperforming the S&P 500. The acquisition aligns with ongoing merger discussions, as BioMarin Pharmaceutical has proposed a buyout of Amicus at $14.50 per share, which could enhance CIBRA’s returns if the deal proceeds as expected.
Investors should consider the implications of CIBRA’s bold move into Amicus, particularly in the context of merger arbitrage strategies. While the acquisition offer appears solid, any failure to close the deal could lead to a sharp decline in Amicus’s stock price, making it a high-risk, high-reward situation for potential investors.
Source: nasdaq.com